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“Outside-to-Inside” (and Now Back 
to “Outside”) Pathogenic Mechanisms 
in Atopic Dermatitis
Peter M. Elias1,2 and Martin Steinhoff 2,3
The pathogenesis of atopic dermatitis (AD) has been attributed largely to 
abnormalities in the adaptive immune system, with key roles played by T-help-
er 1(Th1)/Th2 cell dysregulation, IgE production, dendritic cell signaling, and 
mast-cell hyperactivity, resulting in the pruritic, inflammatory dermatosis that 
characterizes AD (Leung et al., 2004). Accordingly, therapy has been focused 
on ameliorating Th2-mediated inflammation and pruritus (e.g., Leung, 2000). 
Indeed, there is emerging evidence that inflammation in AD results first from 
inherited and acquired insults that converge to alter epidermal structure and 
function, followed by immune system activation, which in turn has negative 
consequences for skin-barrier homeostasis. This cycle comprises an “outside–
inside–outside” model of AD pathogenesis (Elias et al., in press).
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The epidermis generates an impres-
sive set of critical defensive functions 
(Elias, 2005; Elias and Choi, 2005) 
that include the permeability barrier, 
allowing survival in a potentially des-
iccating external environment, and an 
antimicrobial barrier, which simulta-
neously encourages colonization by 
nonpathogenic “normal” flora while 
resisting growth of microbial patho-
gens (Elias, 2007). The permeability 
barrier resides in the stratum corneum 
(SC), where multiple layers of anucleate 
corneocytes are embedded in an extra-
cellular matrix, enriched in ceramides 
(Cer), cholesterol, and free fatty acids, 
arranged as planar lamellar sheets 
(Elias and Menon, 1991). These lipids, 
as well as an assortment of hydrolases 
important for lipid processing and des-
quamation and at least two key anti-
microbial peptides (Aberg et al., 2007, 
and references cited therein), are deliv-
ered to the extracellular matrix through 
secretion of epidermal lamellar body 
contents. Whereas lamellar body–
derived proteases and their inhibitors 
orchestrate the orderly digestion of cor-
neodesmosomes, allowing cells to shed 
invisibly at the skin surface (Brattsand 
et al., 2005; Stefansson et al., 2008), 
the lipid-processing enzymes (β-gluco-
cerebrosidase, acidic sphingomyelin-
ase, and secretory phospholipase A2) 
generate the Cer and free fatty acids 
that, along with cholesterol, form the 
extracellular lamellar membrane (Elias 
and Menon, 1991). Thus, proteases as 
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well as extracellular enzymes may ulti-
mately be involved in the pathophysiol-
ogy of eczema and pruritus.
Based primarily on the strong asso-
ciation of inherited abnormalities in 
filaggrin (FLG) expression, atopic der-
matitis (AD), at least in Euro-Americans, 
is now increasingly considered a prima-
ry disorder of SC structure and function 
(Hudson, 2006; Irvine and McLean, 
2006; Palmer et al., 2006; Smith et al., 
2006; Weidinger et al., 2006). Thus, 
AD can be considered a disease of pri-
mary barrier failure, characterized by 
both a defective permeability (Proksch 
et al., 2006, and references therein) 
and antimicrobial function (Baker, 
2006; Boguniewicz and Leung, 2006). 
Although both of these abnormalities 
are well-recognized features of AD, 
they have been widely assumed to 
reflect downstream consequences of a 
primary immunologic abnormality (the 
historical inside–outside view of AD 
pathogenesis). We and others have long 
proposed that the permeability-bar-
rier abnormality in AD is not merely an 
epiphenomenon but rather the “driver” 
of disease activity (i.e., the reverse, 
outside–inside view of disease patho-
genesis) (Elias and Feingold, 2001), 
because (1) the extent of the permeabil-
ity-barrier abnormality parallels sever-
ity of disease phenotype in AD, (2) both 
clinically uninvolved skin sites and skin 
cleared of inflammation for as long as 
5 years continue to display significant 
barrier abnormalities, (3) emollient 
therapy comprises effective ancillary 
therapy, and (4) specific replacement 
therapy, which targets the prominent 
lipid abnormalities that account for 
the barrier abnormality in AD, not only 
corrects the permeability-barrier abnor-
mality but also comprises effective anti-
inflammatory therapy for AD (Chamlin 
et al., 2002; Figure 1).
Still, how loss of FLG (an intracellular 
protein) provokes a permeability-bar-
|Inﬂammation in AD may begin with insults from without.
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rier abnormality is not known. In addi-
tion, it is not clear what drives barrier 
dysfunction in the skin of AD patients 
without a FLG mutation. Although it 
has been hypothesized that loss of FLG 
could cause corneocyte deformation, 
the barrier abnormality more likely 
is linked to lack of FLG as a substrate 
for proteolytic processing and further 
deimination into polycarboxylic acids, 
such as pyrrolidine carboxylic acid and 
trans-urocanic acid. These metabo-
lites normally act as osmolytes (natural 
moisturizing factors), drawing water 
into corneocytes, partially account-
ing for corneocyte hydration. Hence, 
the most immediate result of FLG defi-
ciency is decreased SC hydration, a 
well-recognized feature of AD. A steep-
er water gradient would inexorably 
accelerate transcutaneous water loss, 
particularly if a paucity of extracellular 
lipids results in decreased water-retain-
ing ability. However, either corneocyte 
flattening or decreased SC hydration 
can suffice to enhance antigen penetra-
tion. We suspect that another mecha-
nism is operative, because another 
inevitable consequence of decreased 
downstream production of polycarbox-
ylic acid metabolites is an increase in 
the SC pH (Krien and Kermici, 2000), 
sufficient to increase the activities of 
the multiple serine proteases in SC, 
which all exhibit neutral-to-alkaline 
pH optima (Brattsand et al., 2005; 
Stefansson et al., 2008; Steinhoff et al., 
2005). Increased serine protease activ-
ity could generate the active forms of 
the primary cytokines IL-1α and IL-1β 
from their 33-kDa pro-forms, which are 
stored in large quantities in the cytosol 
of corneocytes (Hachem et al., 2002; 
Nylander-Lundqvist et al., 1996), the 
first step in the cytokine cascade that 
we propose initiates inflammation in 
AD (Figure 2).
Another cause of inflammation in 
AD doubtless includes sustained anti-
gen ingress through a defective bar-
rier, leading to a T-helper 2 (Th2)-domi-
nant infiltrate (Hudson, 2006). Yet FLG 
mutations alone do not provoke AD, as 
demonstrated in ichthyosis vulgaris, in 
which the same single- or double-allele 
FLG mutations reduce FLG content, but 
inflammation (i.e., AD) does not inevi-
tably occur (Sandilands et al., 2007). 
We and others have suggested that 
certain acquired stressors could elic-
it disease by aggravating the barrier 
abnormality. Indeed, a barrier-depen-
dent increase in pH (and serine protease 
activity) likely accounts for the precipi-
tation of AD following the use of neu-
tral-to-alkaline soaps (Figure 1) (Cork et 
al., 2006). Likewise, prolonged expo-
sure to reduced environmental humid-
ity, a well-known risk factor for AD, 
likely accelerates transcutaneous water 
loss rates across defective SC in AD, 
further aggravating the barrier abnor-
mality. Finally, psychological stress, 
which aggravates permeability-barrier 
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Figure 1.  Secondary infections can further aggravate barrier abnormality in atopic dermatitis. 
AD, atopic dermatitis; AMP, adenosine monophosphate; Cer, ceramide; FLG, filaggrin; LEKTI, 
lymphoepithelial Kazal-type related trypsin inhibitor; PS, psychological stress; RH, relative humidity; 
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Figure 2. “Outside–inside–outside” model of AD. Cer, ceramide; FLG, filaggrin; hBD2, human β-defensin-2; 
Th2, T-helper 2. (From Figure 2. Cer, ceramide; FLG, filaggrin; hBD2, human β-defensin-2; Th2, T-helper 2. 
(From Steinhoff et al., 2005; modified from Elias et al., in press.)
COMMENTARY
 www.jidonline.org 1069
function in humans (Altemus et al., 
2001), is both a well-known precipitant 
of AD and a cause of resistance to ther-
apy. Moreover, a dysregulation of prote-
ases, highly expressed by keratinocytes, 
protease inhibitors, and protease-acti-
vated receptors, may be important for 
neuronal–epidermal communication 
during barrier dysfunction (Demerjian 
et al., 2008; Hachem et al., 2006; 
Steinhoff et al., 2000, 2005).
Despite accumulating evidence in 
support of a barrier-initiated patho-
genesis of AD, recent studies suggest 
specific mechanisms whereby Th2-
generated cytokines could also further 
aggravate AD. As described in this issue 
by Kurahashi et al. (2008), exogenous 
applications of the Th2 cytokine, IL-4, 
impede permeability-barrier recov-
ery after acute perturbations. The basis 
for the negative effects of IL-4 could 
include the prior observation by these 
authors that exogenous IL-4 inhibits 
Cer synthesis (Hatano et al., 2005). But 
IL-4 also inhibits expression of both 
FLG (Howell et al., 2007) and desmo-
glein 3 (Kobayashi et al., 2004), which 
also could further compromise barrier 
function, completing a potential out-
side–inside–outside pathogenic loop in 
AD (Figure 2). Furthermore, nerves may 
be activated by “barrier stressors” such 
as UV light, toxic or allergic agents, 
and microbial agents. Therefore, nerve-
derived mediators could also modulate 
enzyme production, antimicrobial pep-
tide (defensin) generation, pH changes, 
or SC humidity, thereby influencing 
keratinocyte function (Paus et al., 2006; 
Roosterman et al., 2006; Steinhoff et 
al., 2006).
Together, the converging pathogenic 
features described above create a strong 
rationale for the deployment of specific 
strategies to restore barrier function in 
AD. When used under nursing super-
vision, moisturizers have been shown 
to reduce topical steroid usage (Cork 
et al., 2003). Of various barrier-repair 
approaches, a mixture of the three SC 
lipids in a Cer-dominant formulation 
(TriCeram, Osmotics Cosmeceuticals) 
demonstrated improved clinical sta-
tus, permeability-barrier function, and 
SC integrity when this technology was 
substituted for standard moisturizers in 
children with severe, recalcitrant AD 
(Chamlin et al., 2002). More recently, 
a higher-strength, FDA cleared formu-
lation (EpiCeram cream, Ceragenix 
Pharmaceuticals) demonstrated efficacy 
that was comparable to that of a mid-
potency steroid (fluticasone; Cutivate 
cream) in an investigator-blinded, 
multicenter clinical trial of pediat-
ric patients with moderate to severe 
AD (Sugarman and Parish, in press). 
These studies, although still prelimi-
nary, suggest that correction of the lipid 
biochemical abnormality that is respon-
sible for the barrier defect in AD could 
also downregulate the further inside-
to-outside alterations provoked by IL-4 
and could comprise a new or ancillary 
approach to the therapy of AD.
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